Laquinimod data demonstrates neuroprotective properties
Posted: Fri Oct 15, 2010 10:36 pm
Teva Pharmaceutical Industries Ltd. and Active Biotech announced that data providing further evidence of the neuroprotective properties of laquinimod in animal studies were presented at the 26th Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) in Gothenburg, Sweden. Laquinimod is an investigational, once-daily oral immunomodulator for the treatment of relapsing remitting multiple sclerosis (RRMS).
These results, generated from several pre-clinical studies evaluating the mechanism of action (MOA) of oral laquinimod, demonstrated that:... Read More - http://www.msrc.co.uk/index.cfm/fuseact ... ageid/1735